Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON (Reuters) - Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.